Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Expansion Into China's Lower-tier Cities Could Be Growth Driver For Big Pharma

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's pharma market is expected to continue to grow in the next five years with a CAGR of 23.2%, which will be backed largely by the expansion of community health centers across tier 2 and tier 3 cities, according to a report issued by consultancy IMS Health
Advertisement

Related Content

China's Changing Reimbursement Landscape Reshapes Pharma Market
Novo Ramps Up In China, Roche Downplays Branded Generics, GSK Talks Up Japan While Hitting "The Inflection Point": Emerging Markets Round Up (Part 2)
Pfizer Looks To Ramp Up Branded Generics Via MOU With China's Hisun
China's Outsource Sales Model Takes A Big Step: SciClone Takes Out NovaMed
Chinese Local Pharmas See Innovative Products As Future Growth Driver - China Healthcare Investment Conference
Chinese Local Pharmas See Innovative Products As Future Growth Driver - China Healthcare Investment Conference
Victoza Approved In China: Novo Nordisk Gears Up To Conquer China's Diabetes Market
Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields
Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields
China's Big Cities Should Be First Priority For Pharma Companies - IMS
Advertisement
UsernamePublicRestriction

Register

SC077221

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel